ArticleNews reportPHN-06382026-11-04 09:00 CT

This MIT Scientist Injected SS31 Peptide for 20 Years. Now It's FDA Approved and Targeting Mitochondria in Ways No Drug Ever Has

Source · BoxLife Magazine

TLDR

BoxLife Magazine reports that Stealth BioTherapeutics’ SS-31 (elamipretide) received FDA approval in 2025 for Barth syndrome. Reviewing David Sinclair’s podcast discussion, the article distinguishes condition-specific approvals from longevity claims, which Sinclair says remain largely supported by animal studies, cell research and anecdotes.

01—Key points

01The article describes elamipretide as a mitochondria-targeting drug; benefits beyond Barth syndrome remain unproven.
02Sinclair highlighted limited human evidence for BPC-157 and TB-500 and predominantly preclinical findings for several experimental peptides.
03The discussion raised concerns about gray-market product purity and contamination, and uncertainties around long-term growth hormone stimulation.

Why it matters Editorial

The article highlights the distinction between regulatory approval for specific diseases and evidence supporting broader peptide-based longevity claims.

Read the original at BoxLife Magazine↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.